Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid

International Journal of Hyperthermia

Volumn 20, Issue 4, 2004, Pages 393-404

  Murata, R ^a   Horsman, Mike R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

C3H mammary carcinoma; DMXAA; Hyperthermia; Radiation; Vascular targeting

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; SODIUM CHLORIDE; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CONTROL; CHI SQUARE TEST; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOOT; HEATING; HYPERTHERMIC THERAPY; MOUSE; MOUSE STRAIN; NONHUMAN; RADIATION DOSE; SKIN EXFOLIATION; SKIN TUMOR; STATISTICAL SIGNIFICANCE; TEMPERATURE MEASUREMENT; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HYPERTHERMIA, INDUCED; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; SKIN; TEMPERATURE; XANTHONES;

EID: 3042644639     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.1080/02656730310001619370     Document Type: Article

References (58)

1. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metas Rev 1990; 9: 267-82.
2. Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999; 80(Suppl. 1): 57-64.
3. Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiother Oncol 2000; 57: 5-12.
4. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 1994; 29: 373-7.
5. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 1994; 6: 79-85.
6. Laws AL, Matthew AM, Double JA, Bibby MC. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995; 71: 1204-9.
7. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998; 78: 439-45.
8. Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001; 77: 195-204.
9. Rustin G, Galbraith S, Taylor N, Stratford M, Bradley C, Thompson P, Jameson M, Baguley B. Impact on tumour perfusion measured by dynamic magnetic resonance imaging (MRI), in the phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Ann Oncol 1998; 9: 126.
10. Ching L-M, Joseph WR, Zhuang L, Baguley BC. Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours. Cancer Chemother Pharmacol 1994; 35: 153-60.
11. Philpott M, Baguley BC, Ching L-M. Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1995; 36: 143-8.
12. Ching L-M, Xu Z-F, Gummer BH, Palmer BD, Joseph WR, Baguley BC. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995; 72: 339-43.
13. Browne WL, Wilson WR, Baguley BC, Ching L-M. Suppression of serum tumour necrosis factor-α by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. Anticancer Res 1998; 18: 4409-14.
14. Cao Z, Joseph WR, Browne WL, Mountjoy KG, Palmer BD, Baguley BC, Ching L-M. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1999; 80: 716-23.
15. Ching L-M, Goldsmith D, Joseph WR, Koerner H, Sedgwick JD, Baguley BC. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 1999; 59: 3304-7.
16. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Kestell P. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Proc Am Soc Clin Oncol 2000; 19: 182a.
17. Philpott M, Ching L-M, Baguley BC. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor. Eur J Cancer 2001; 37: 1930-7.
18. Zhao L, Ching L-M, Kestell P, Baguley BC. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 2002; 87: 465-70.
19. Ching L-M, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC. Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 2002; 86: 1937-42.
20. Thomsen LL, Ching L-M, Zhuang L, Gavin JB, Baguley BC. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 1991; 51: 77-81.
21. Moilanen E, Thomsen LL, Miles DW, Happerfield L, Knowles RG, Moncada S. Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1998; 77: 426-33.
22. Baguley BC, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastin, and colchicine: relation to vascular effects. Oncol Res 1997; 9: 55-60.
23. Pang J-H, Cao Z, Joseph WR, Baguley BC, Ching L-M. Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor. Eur J Cancer 1998; 34: 1282-9.
24. Cao Z, Baguley BC, Ching L-M. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res 2001; 61: 1517-21.
25. Wilson WR, Li AE, Cowan DSM, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 1998; 42: 905-8.
26. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 2001; 156: 503-9.
27. Murata R, Overgaard J, Horsman MR. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2001; 17: 508-19.
28. Pruijin FB, van Daalen M, Holford NHG, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997; 39: 541-6.
29. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002; 99: 1-6.
30. Ching LM, Browne WL, Tchernegovski R, Gregory T, Baguley BC, Palmer BD. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. Br J Cancer 1998; 78: 336-43.
31. Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, Begent RHJ. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996; 56: 3293-300.
32. Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RHJ. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 1999; 59: 3998-4003.
33. Kanwar JR, Kanwar RK, Pandey S, Ching L-M, Krissansen GW. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1(CD80)-mediated immunotherapy overcomes immune resistance and leads to eradication of large tumors and multiple tumor foci. Cancer Res 2001; 61: 1948-56.
34. Overgaard J. Rationale and problems in the design of clinical trials. In: Overgaard J, ed. Hyperthermic Oncology 1984, Vol. 2, London: Taylor & Francis, 1985: 325-38.
35. Overgaard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys 1989; 16: 535-49.
36. Horsman MR, Overgaard J. Overcoming tumour radioresistance resulting from hypoxia. In: Steel GG, ed. Basic Clinical Radiobiology for Radiation Oncologists 3rd edn, London: Edward Arnold, 2002: 169-81.
37. Dewhirst MW, Prosnitz L, Thrall D, Prescott D, Clegg S, Charles C, MacFall J, Rosner G, Samulski T, Gillette E, LaRue S. Hyperthermic treatment of malignant diseases: current status and a view toward the future. Semin Oncol 1997; 24: 616-25.
38. Horsman MR, Overgaard J. Thermal radiosensitization in animal tumors: the potential for therapeutic gain. In: Urano M, Douple E, eds. Hyperthermia and Oncology, Vol. II, Utrecht: VSP, 1989: 113-45.
39. Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol 2001; 40: 497-503.
40. Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: A vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 2001; 51: 1018-24.
41. Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980; 6: 1507-17.
42. Horsman MR, Christensen KL, Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int J Hyperthermia 1989; 5: 123-36.
43. Horsman MR, Sampson LE, Chaplin DJ, Overgaard J. The in vivo interaction between flavone acetic acid and hyperthermia. Int J Hyperthermia 1996; 12: 779-89.
44. Horsman MR, Murata R. Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 2002; 54: 1518-23.
45. Hallahan DE, Beckett MA, Kufe D, Weichselbaum RR. The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int J Radiat Oncol Biol Phys 1990; 19: 69-74.
46. Kimura K, Bowen C, Spiegel S, Gelmann EP. Tumor necrosis factor-α sensitizes prostate cancer cells to γ -irradiation-induced apoptosis. Cancer Res 1999; 59: 1606-14.
47. Gerweck LE, Nygaard TG, Burlett M. Response of cells to hyperthermia under acute and chronic hypoxic conditions. Cancer Res 1979; 39: 966-72.
48. Overgaard J, Nielsen OS. The role of tissue environmental factors on the kinetics and morphology of tumor cells exposed to hyperthermia. Ann NY Acad Sci 1980; 335: 254-80.
49. Kallinowski F, Moehle R, Vaupel P. Substantial enhancement of tumor hyperthermic response by tumor necrosis factor. In: Sugahara T, Saito M, eds. Hyperthermic Oncology, Vol. I, London: Taylor & Francis, 1989: 258-9.
50. Lin JC, Park HJ, Song CW. Combined treatment of IL-1α and TNF-α potentiates the antitumour effect of hyperthemia. Int J Hyperthermia 1996; 12: 335-44.
51. Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 1988; 48: 650-3.
52. Van Molle W, Wielockx B, Mahieu T, Takada M, Taniguchi T, Sekikawa K, Libert C. HSP70 protects against TNF-induced lethal inflammatory shock. Immunity 2002; 16: 685-95.
53. Song CW, Park H, Griffin RJ. Improvement of tumor oxygenation by mild hyperthermia. Radiat Res 2001; 155: 515-28.
54. Burd R, Dziedzic TS, Xu Y, Caligiuri MA, Subjeck JR, Repasky EA. Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. J Cell Physiol 1998; 177: 137-47.
55. Park MM, Hornback NB, Endres S, Dinarello CA. The effect of whole body hyperthermia on the immune cell activity of cancer patients. Lymphokine Res 1990; 9: 213-23.
56. Katschinski DM, Wiedemann GJ, Longo W, d'Oleire FR, Spriggs D, Robins HI. Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapy. Cytokine Growth Factor Rev 1999; 10: 93-7.
57. Payne J, Nair MPN, Ambrus JL, Chadha KC. Mild hyperthermia modulates biological activities of interferons. Int J Hyperthermia 2000; 16: 492-507.
58. Overgaard J, Horsman MR. Hyperthermic radiosensitization in the treatment of solid tumours - experience from mice and man. In: Hagen U, Harder D, Jung H, Streffer C, eds. Radiation Research 1895-1995, Vol. 2. Congress Lectures, Würzburg: Universitätsdruckerei H. Stürtz AG, 1995: 997-1000.